View More Recent Stories
-
United Therapeutics Corp. (UTHR) PT Raised to $575 at Oppenheimer
-
United Therapeutics Corp. (UTHR) PT Raised to $560 at UBS
-
United Therapeutics (UTHR) call put ratio 1 call to 6.3 puts with a focus on October and November puts as share price up 33%
-
United Therapeutics Corp. (UTHR) PT Raised to $564 at Jefferies
-
United Therapeutics' Tyvaso meets primary endpoint in IPF study
-
MannKind expands United Therapeutics partnership for second inhaled therapy
-
UBS Reiterates Buy Rating on United Therapeutics Corp. (UTHR)
-
Cantor Fitzgerald Reiterates Overweight Rating on United Therapeutics Corp. (UTHR)
-
United Therapeutics Corp. (UTHR) PT Raised to $415 at UBS
-
United Therapeutics Corp. (UTHR) PT Lowered to $400 at H.C. Wainwright
-
United Therapeutics (UTHR) Misses Q2 EPS by 94c
-
United Therapeutics Corp. (UTHR) PT Lowered to $385 at UBS
-
United Therapeutics (UTHR) Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
-
Leerink on Insmed (INSM) as Shares Surge 26pct: 'we continue to view INSM as a core Rare Disease/blockbuster platform'
-
Leerink Partners Reiterates Outperform Rating on United Therapeutics Corp. (UTHR)
-
Raymond James on Liquidia Technologies (LQDA): 'we maintain our positive outlook for the simultaneous Yutrepia launches in PAH and PH-ILD'
-
TD Cowen: 'We Continue to See United Therapeutics Corp. (UTHR) Shares as Undervalued'
-
United Therapeutics Corp. (UTHR) PT Raised to $321 at BofA Securities
-
United Therapeutics (UTHR) Tops Q1 EPS by 10c
-
Wells Fargo Downgrades United Therapeutics Corp. (UTHR) to Equal Weight
-
BofA Securities Upgrades United Therapeutics Corp. (UTHR) to Neutral
-
United Therapeutics Corp. (UTHR) PT Lowered to $293 at Goldman Sachs
-
United Therapeutics (UTHR) Misses Q4 EPS by 49c
-
United Therapeutics (UTHR) Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
United Therapeutics (UTHR) Announces Successful World’s First UKidney Transplant
-
United Therapeutics Corp. (UTHR) PT Raised to $344 at Ladenburg Thalmann
-
United Therapeutics Corp. (UTHR) PT Raised to $425 at H.C. Wainwright
-
United Therapeutics (UTHR) Misses Q3 EPS by 14c
-
LifeSci Capital Reiterates Outperform Rating on Liquidia Technologies (LQDA)
-
United Therapeutics Corp. (UTHR) PT Raised to $432 at Jefferies
-
United Therapeutics Corp. (UTHR) PT Raised to $575 at Oppenheimer
-
United Therapeutics Corp. (UTHR) PT Raised to $380 at Wells Fargo
-
Goldman Sachs Reiterates Neutral Rating on United Therapeutics Corp. (UTHR)
-
TD Cowen Reiterates Buy Rating on United Therapeutics Corp. (UTHR)
-
United Therapeutics (UTHR) Misses Q2 EPS by 63c
-
United Therapeutics Corp. (UTHR) PT Raised to $400 at H.C. Wainwright
-
United Therapeutics Corp. (UTHR) PT Raised to $350 at TD Cowen
-
Morgan Stanley Downgrades United Therapeutics Corp. (UTHR) to Equalweight
-
United Therapeutics Corp. (UTHR) PT Raised to $350 at Argus
-
United Therapeutics Corp. (UTHR) PT Raised to $370 at UBS
-
United Therapeutics (UTHR) Appoints Jan Malcolm to its Board
-
United Therapeutics Corp. (UTHR) PT Lowered to $262 at BofA Securities
-
Grow your wealth: UBS reveals top long-term stock picks
-
Martine Rothblatt is Featured in Forbes Magazine's Special Centennial Issue as one of The World's 100 Greatest Living Business Minds

